Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.84 |
| ▸ | KIT | P10721 | 5/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | FLT3 | P36888 | 1/20 | 0.73 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22548931 | 0.91 | ABL1 (1.00) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL28516136 | 0.90 | ABL1 (0.87) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL24626764 | 0.90 | KIT (0.79) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL31620766 | 0.88 | KIT (1.00) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL28516830 | 0.88 | ABL1 (0.82) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL28515378 | 0.88 | ABL1 (0.82) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL31620735 | 0.87 | KIT (1.00) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL4112245 | 0.87 | ABL1 (1.00) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL28512787 | 0.87 | ABL1 (0.80) | ABL1KITFGFR1CYP2C9PDGFRA | |
| SCHEMBL22549164 | 0.86 | KIT (0.84) | ABL1KITFGFR1CYP2C9PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020206583-A1 | KINASE INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-10-15 | — | — | WO | disclosed |